Inspire Medical Systems Announced FDA Approval for Apnea Hypopnea Index Indication Expansion and Increased Body Mass Index Labeling
Portfolio Pulse from Charles Gross
Inspire Medical Systems (NYSE:INSP) has received FDA approval for an expanded indication, increasing the upper limit of the Apnea Hypopnea Index (AHI) to 100 events per hour from 65, and raising the Body Mass Index (BMI) warning in the labeling to 40 from 32.
June 09, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inspire Medical Systems has received FDA approval for an expanded indication, which may lead to increased adoption of their products.
The FDA approval for an expanded indication allows Inspire Medical Systems to target a larger patient population with obstructive sleep apnea. This may lead to increased adoption of their products, positively impacting their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100